In this study, we first investigated the expression levels of CD46 in various tumors using tissue microarrays, demonstrating that CD46 overexpression was prevalent in prostate cancers (PCa) and colorectal cancers (CRC). The gene discussed is CD46; the disease is prostate carcinoma.